Sterling Pharma Solutions: acquisition of ADC Biotechnology
Global CDMO Sterling Pharma Solutions has acquired ADC Biotechnology, a U- based bioconjugation development services business focused on antibody drug conjugates (ADCs). The organization’s facility in North Wales will be rebranded as part of the Sterling Pharma Solutions international network.
Kevin Cook, CEO at Sterling Pharma Solutions, said: “We are delighted to confirm the acquisition of the ADC Bio business; this investment provides us with the opportunity to offer a wider portfolio of services to our customers in the fast growing ADC and bioconjugation market, as well as providing additional services to existing ADC Bio customers."
